STAT+: Merck suffers a setback in Europe over its new Keytruda formulation

The Dutch court has ordered a halt to the manufacturing and marketing of a subcutaneous formulation of Merck's Keytruda in several European countries. This decision comes as a setback for the pharmaceutical company, which had hoped to expand the use of its cancer drug. The court's ruling follows a patent infringement lawsuit brought by a rival company.